Serina Therapeutics, Inc. - 8-K Filing
Serina Therapeutics advances SER-252 to Cohort 2 in Phase 1b Parkinson's study after positive blinded review of Cohort 1 data (Items: 8.01 Other Items)
Tickers: $SER
Serina Therapeutics advances SER-252 to Cohort 2 in Phase 1b Parkinson's study after positive blinded review of Cohort 1 data (Items: 8.01 Other Items)
Tickers: $SER